Bicocca Open Archive

Logo unimib boa
REDAELLI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.462
EU - Europa 3.919
AS - Asia 3.897
SA - Sud America 588
Continente sconosciuto - Info sul continente non disponibili 380
AF - Africa 102
OC - Oceania 13
Totale 18.361
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.967
SG - Singapore 1.405
IT - Italia 903
CN - Cina 895
DE - Germania 753
VN - Vietnam 527
RU - Federazione Russa 478
BR - Brasile 427
HK - Hong Kong 406
SE - Svezia 392
CA - Canada 379
IE - Irlanda 379
UA - Ucraina 240
GB - Regno Unito 229
FR - Francia 173
IN - India 149
FI - Finlandia 100
BD - Bangladesh 75
TR - Turchia 73
AR - Argentina 59
PL - Polonia 52
IQ - Iraq 51
KR - Corea 51
ES - Italia 46
ID - Indonesia 40
ZA - Sudafrica 40
JP - Giappone 37
NL - Olanda 37
BE - Belgio 34
PK - Pakistan 33
MX - Messico 30
AT - Austria 28
CO - Colombia 28
DK - Danimarca 27
VE - Venezuela 24
SA - Arabia Saudita 22
EC - Ecuador 17
JM - Giamaica 16
PH - Filippine 16
UZ - Uzbekistan 16
AU - Australia 12
AZ - Azerbaigian 12
CR - Costa Rica 11
MA - Marocco 11
SV - El Salvador 11
CL - Cile 10
JO - Giordania 10
KE - Kenya 10
TT - Trinidad e Tobago 10
EU - Europa 9
IR - Iran 9
MY - Malesia 9
EG - Egitto 8
ET - Etiopia 8
LT - Lituania 8
PE - Perù 8
TN - Tunisia 8
BG - Bulgaria 7
HN - Honduras 7
NI - Nicaragua 7
NP - Nepal 7
PY - Paraguay 7
TH - Thailandia 7
BO - Bolivia 6
CH - Svizzera 6
CZ - Repubblica Ceca 6
DO - Repubblica Dominicana 6
IL - Israele 6
OM - Oman 6
AE - Emirati Arabi Uniti 5
CW - ???statistics.table.value.countryCode.CW??? 5
PR - Porto Rico 5
GE - Georgia 4
GT - Guatemala 4
PS - Palestinian Territory 4
RO - Romania 4
AM - Armenia 3
KG - Kirghizistan 3
LB - Libano 3
MU - Mauritius 3
NO - Norvegia 3
PA - Panama 3
PT - Portogallo 3
RS - Serbia 3
TW - Taiwan 3
AO - Angola 2
BS - Bahamas 2
DZ - Algeria 2
NG - Nigeria 2
SN - Senegal 2
UY - Uruguay 2
BA - Bosnia-Erzegovina 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BW - Botswana 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
Totale 17.975
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.126
Ashburn 1.060
Singapore 831
Woodbridge 589
San Jose 537
Fairfield 455
Hong Kong 396
Frankfurt am Main 386
Chandler 372
Dublin 367
Milan 347
Houston 317
Wilmington 262
Dearborn 235
Jacksonville 228
Toronto 216
New York 193
Council Bluffs 192
Seattle 189
Ho Chi Minh City 150
Los Angeles 150
Beijing 143
Cambridge 137
Santa Clara 137
Dallas 135
Chicago 122
Hanoi 113
The Dalles 104
Princeton 101
Shanghai 80
Göttingen 75
Nanjing 73
Hefei 64
Munich 63
Boardman 57
Lauterbourg 54
Altamura 49
São Paulo 45
Seoul 43
Lawrence 42
Moscow 39
Rome 39
Buffalo 38
Lachine 37
London 35
Brussels 34
Helsinki 32
Tokyo 31
Warsaw 30
Da Nang 29
Nanchang 29
Columbus 26
Dong Ket 26
Jakarta 26
Montreal 26
San Diego 26
Denver 25
Fremont 25
Fürstenwalde 25
Phoenix 25
Shenyang 25
Brooklyn 23
Guangzhou 23
Orem 23
Atlanta 22
Philadelphia 22
Turku 22
Johannesburg 21
Tianjin 21
Chennai 20
Vienna 20
Nuremberg 19
Ottawa 19
Andover 18
Changsha 18
Haiphong 18
Salt Lake City 18
Falls Church 16
Rio de Janeiro 16
Baghdad 15
Charlotte 15
Jiaxing 15
Lodz 15
Manchester 15
Pune 15
San Francisco 15
Washington 15
Düsseldorf 14
Hangzhou 14
Jinan 14
Mumbai 14
Tashkent 14
Kocaeli 13
Lissone 13
Romola 13
Ankara 12
Buenos Aires 12
Hebei 12
Monza 12
Stockholm 12
Totale 11.511
Salva come PNG Salva come JPEG
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 650
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 603
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 489
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 452
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 446
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 446
Idiopathic erythrocytosis: a germline disease? 431
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 423
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 422
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 407
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 399
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 399
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 386
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 385
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 375
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 371
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 366
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 359
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 356
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 354
Dual kinase targeting in leukemia 350
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 347
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 344
Inhibition of RET tyrosine kinase by SU5416 344
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 338
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 338
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 334
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 332
Identification of a Novel Splicing Mutation in Blast Crisis Transformation of Chronic Myeloid Leukemia Integrating Whole-exome and RNA-Seq data 325
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 318
Reply to P. Laneuville et al 315
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 314
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 309
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 309
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 299
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia 298
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 297
Expression, purification, and inhibition of human RET tyrosine kinase 297
Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib 293
Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants 286
Volatile Sedation for Acute Respiratory Distress Syndrome Patients on Venovenous Extracorporeal Membrane Oxygenation and Ultraprotective Ventilation 277
BCR and BCR/ABL Regulation during Myeloid Differentiation in Healthy Donors and in Chronic Phase/Blast Crisis CML Patients 275
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 271
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 269
Bosutinib is a Substrate of the ABC Efflux Transporter P-Glycoprotein 265
Novel targeted therapeutics for MEN2 264
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBa mediated p53 nuclear exclusion 252
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic 247
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 247
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma 240
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 231
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 216
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 212
Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform InfraRed microspectroscopy and unsupervised Hierarchical Cluster Analysis. 189
Totale 18.361
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.878
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.878
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022495 0 0 0 0 51 70 38 34 37 81 64 120
2022/20231.491 169 461 145 151 93 197 18 81 84 23 33 36
2023/20241.066 28 34 43 60 139 299 217 38 54 23 15 116
2024/20252.250 141 224 153 129 203 72 151 89 194 378 196 320
2025/20265.911 693 283 487 623 747 285 846 224 466 565 343 349
2026/20271.642 137 239 490 704 72 0 0 0 0 0 0 0
Totale 18.361